Clinical operations

A Green Enrollment Dashboard Can Hide a Site Capacity Problem

Learn how to review staffing continuity, critical backlogs and decision ownership alongside enrollment totals in oncology trials.

By Lampgen Clinical Research

A green indicator in front of a busy research desk, illustrating why enrollment alone may miss capacity pressures.
Conceptual editorial illustration; it does not depict an observed study procedure, actual patient data or a demonstrated treatment outcome.

3 min read · estimated

Sources
Enrollment is an outputCapacity sustains delivery
Proposed operational framework; warning signals require investigation.

What the source reported

FDA’s risk-based monitoring guidance supports focusing oversight on processes and data important to participant protection and reliable results, with clear escalation of important findings. [1] Its investigator-responsibilities guidance addresses supervision when study work is delegated. [2] Neither document establishes a universal coordinator-to-protocol ratio or a single dashboard score that proves a site has sufficient capacity.

What this means for trial teams

Lampgen’s analysis: enrollment is a useful result, but it is an incomplete measure of a site’s ability to sustain study delivery. A participant enrolled this month can create appointments, specimen work, safety documentation and follow-up obligations for months afterward. A dashboard that counts only new enrollment may miss that accumulating work.

Consider an illustrative situation: recruitment remains on target, a coordinator leaves, and a trained backup is unavailable for a time-sensitive procedure. Nothing about the enrollment total tells the team whether that next procedure can be delivered reliably. This scenario is hypothetical; it is not an account of a particular sponsor or site.

A capacity review should ask four connected questions. What changed in staffing or coverage? Which critical tasks are becoming late or repeatedly reassigned? What consequence could follow if the pattern continues? Who has authority to provide support or change the plan? Each answer should lead to a decision, rather than a new column of unowned metrics.

Look at backlog composition before volume. Ten routine queries and one unresolved eligibility discrepancy are different problems. Review the age, importance and reason for delay, together with the next scheduled participant activity. The same applies to training: a completed record does not, by itself, establish that a backup can perform the required task at the required time.

Escalation should be concise and usable. Describe the observation, the potential consequence, the information still missing, the action requested and the date a decision is needed. Avoid diagnosing burnout or poor performance from a dashboard. Ask the investigator and site team to help determine whether the issue involves workload, systems, training, competing priorities or another cause.

A proposed resolution also needs a verification step. If additional support is assigned, specify what it will own and how the team will know the critical task is again under control. An action marked complete may show that a meeting occurred; it does not necessarily show that the operational constraint has been removed.

The significance for oncology trials is practical: planning has to protect the work already committed to participants as well as the next enrollment milestone. Lampgen recommends reviewing active-patient workload, coverage and critical outstanding work together. These are proposed management practices, with thresholds tailored to the study. They do not prove that a site is unsafe or replace investigator oversight.

When evaluating a CRA or CTM assignment, define the capacity question first. The useful contribution may be focused monitoring coverage, structured follow-up or study-level coordination. Adding a person helps only when the responsibilities, access and decision route are clear.

Sources

  1. FDA — Risk-Based Monitoring Questions and Answers, April 2023
  2. FDA — Investigator Responsibilities

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?